Hepatopulmonary Shunt Reduction With Lu-177-DOTATATE Therapy

Acar E., ÇAPA KAYA G., Durak H.

CLINICAL NUCLEAR MEDICINE, vol.41, no.11, pp.866-871, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Editorial Material
  • Volume: 41 Issue: 11
  • Publication Date: 2016
  • Doi Number: 10.1097/rlu.0000000000001352
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.866-871
  • Keywords: hepatopulmonary shunt, Lu-177-DOTATATE therapy, neuroendocrine tumor, radioembolization, Y-90, HEPATOCELLULAR-CARCINOMA, Y-90 RADIOEMBOLIZATION
  • Dokuz Eylül University Affiliated: Yes


A 72-year-old man was diagnosed with well-differentiated neuroendocrine tumor of unknown primary with liver metastasis. All liver lesions were detectable only on Ga-68-DOTATATE PET/CT and were negative on F-18-FDG PET/CT. Intrahepatic Y-90 radioembolization therapy was planned, but the hepatopulmonary shunt fraction was found to be 31.6%. Because the hepatopulmonary shunt fraction greater than 20% is an absolute contraindication to radioembolization, we decided to give him Lu-177-DOTATATE therapy. He received 4 courses of Lu-177-DOTATATE and showed regression in posttherapy Ga-68-DOTATATE PET/CT imaging. The hepatopulmonary shunt fraction was reduced to 8% after Lu-177-DOTATATE therapy.